Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models

British Journal of Cancer

Volumn 110, Issue 7, 2014, Pages 1733-1743

  Cao, S ^a   Durrani, F A ^a   Toth K ^a   Rustum, Y M ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

antitumour activity; cisplatin; cyclophosphamide; irinotecan; oxaliplatin; Se methylselenocysteine; toxicity profile

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CREATININE; CYCLOPHOSPHAMIDE; IRINOTECAN; OXALIPLATIN; SE METHYLSELENOCYSTEINE; SELENIUM DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER INHIBITION; COLORECTAL CARCINOMA; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG POTENTIATION; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEMORRHAGIC CYSTITIS; LETHAL DOSE; MAXIMUM TOLERATED DOSE; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; STOMATITIS; TREATMENT DURATION; TUMOR XENOGRAFT; UREA NITROGEN BLOOD LEVEL; WEIGHT REDUCTION; ALOPECIA; CANCER MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG INTOXICATION; HISTOPATHOLOGY; INFANT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOPROTECTION; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; RATS; RATS, INBRED F344; SELENOCYSTEINE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84897575780     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.85     Document Type: Article

References (38)

1. Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH (2005) Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 23: 9243-9249.
2. Amaral AF, Cantor KP, Silverman DT, Malats N (2010) Selenium and bladder cancer risk: a meta analysis. Cancer Epidemiol Biomarkers Prev 199: 2407-2415.
3. Anton E (2002) Delayed toxicity of cyclophosphamide on the bladder of DBA/2 and C57BL/6 female mouse. Int J Exp Pathol 83: 47-53.
4. Antunes LMG, Darin JD, Bianchi MDLP (2001) Effects of the antioxidants curcumin or selenium on cisplatin-induced nephrotoxicity and lipid peroxidation in rats. Pharmacol Res 43: 145-150.
5. Antunes LM, Francescato HD, Darin JD, de Lourdes P Bianchi M (2000) Effects of selenium pretreatment on cisplatin-induced chromosome aberrations in wister rats. Teratog Carcinog Mutagen 20: 341-348.
6. Azrak RG, Cao S, Pendyala L, Durrani FA, Prey J, Combs J, Fakih M, Rustum YM (2007) Plasma, normal and tumor tissue selenium concentrations as a function of 5-methyl-selenocysteine dose in mice bearing human tumor xenografts. Biochem Pharmacol 73: 1280-1287.
7. Baldew GS, Van Der Hamer CJ, Los G, Vermeulen NP, de Goeij JJ, McVie JG (1989) Selenium-induced protection against cis-diamminedichloroplatinum(II) nephrotoxicity in mice and rats. Cancer Res 49: 3020-3030.
8. Bhattacharya A, Seshadri M, Oven S, Toth K, Vaughan M, Rustum YM (2008) Tumor vascular maturation and improved drug delivery induced by Methyl-selenocysteine leads to therapeutic synergy with anticancer drugs. Clin Cancer Res 14: 3926-3932.
9. Bhattacharya A, Toth K, Sen A, Seshadri M, Cao S, Durrani F, Faber E, Repasky EA, Rustum YM (2009) Inhibition of colon cancer growth by MethylSelenocysteine-induced angiogenic chemomodulation is influenced by histologic characteristics of the tumor. Clin Colorectal Cancer 8: 155-162.
10. Bleiberg H (1998) Oxaliplatin (L-OHP): a new reality in colorectal cancer. Br J Cancer 77(Suppl 4): 1-3.
11. Botchkarev VA, Komarova EA, Siebenhaar F, Botchkareva NV, Komarov PG, Maurer M, Gilchrest BA, Gudkov AV (2000) p53 is essential for chemotherapy-induced hair loss. Cancer Res 60: 5002-5006.
12. Brinkman M, Reulen RC, Kellen E, Buntinx F, Zeegers MP (2006) Are men with low selenium levels at increased risk of prostate cancer? Eur J Cancer 42: 2463-2471.
13. Camargo SM, Francescato HD, Lavrador MA, Bianchi ML (2001) Oral administration of sodium selenite minimizes cisplatin toxicity on proximal tubules of rats. Biol Trace Elem Res 83: 251-262.
14. Cao S, Bhattacharya A, Durrani FA, Fakih M (2006) Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Expert Opin Pharmacother 7: 687-703.
15. Cao S, Durrani FA, Rustum YM (2004) Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts. Clin Cancer Res 10: 2561-2569.
16. Cao S, Rustum YM (2000) Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose. Cancer Res 60: 3717-3721.
17. Cao S, McGuire JJ, Rustum YM (1999) Antitumor activity of ZD1694 (Tomudex) against human head and neck cancer in dude mouse models: role of doing schedule and plasma thymidine. Clin Cancer Res 5: 1925-1934.
18. Chen CS, Lin J, Gross K, He YA, Halpert J, Waxman D (2004) Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics. Mol Pharmacol 65: 1278-1287.
19. Chintala S, Toth K, Cao S, Durrani FA, Vaughan MM, Jenesen RL, Rustum YM (2010) Se-Methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1a. Cancer Chemother Pharmacol 66(5): 899-911.
20. Chintala S, Najrana T, Toth K, Cao S, Durrani FA, Pili R, Rustum YM (2012) Prolyl Hydroxylase 2-dependent and Von-Hippel-Lindu-independent degradation of hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition. BMC Cancer 12: 293.
21. Clark LC, Cantor KP, Allaway WH (1991) Selenium in forage crops and cancer mortality in U.S. counties. Arch Environ Health 46: 37-42.
22. Clark LC, Combs Jr GF, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Lesher Jr JL, Park HK, Sanders Jr BB, Smith CL, Taylor JR (1996) Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA 276: 1957-1963.
23. Fakih MG, Pendyala L, Smith PF, Creaven PJ, Reid ME, Badmaev V, Azrak RG, Prey JD, Lawrence D, Rustum YM (2006) A phase I and pharmacokinetic study of fixed-dose selenomethionine and irintoecan in solid tumors. Clin Cancer Res 12: 1237-1244.
24. Fakih MG, Pendyala L, Brady W, Smith PF, Ross ME, Creaven PJ, Badmaev V, Prey JD, Rustum YM (2008) A phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumors. Cancer Chemother Pharmacol 62(3): 499-508.
25. Fraiser LH, Kanekal S, Kehrer JP (1991) Cyclophosphamide toxicity. Characterizing and avoiding the problem. Drugs 42: 781-795.
26. Hu YJ, Chen Y, Zhang YQ, Zhou MZ, Song XM, Zhang BZ, Luo L, Xu PM, Zhao YN, Zhao YB, Cheng G (1997) The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients. Biol Trace Elem Res 56(3): 331-341.
27. Ibrahim A, Hirschfeld S, Cohen MH, Griebel DJ, Williams GA, Pazdur R (2004) FDA drug approval summaries: oxaliplatin. Oncologist 9: 8-12.
28. Ip C, Shu Z, Thompson HJ, Lisk D, Ganther HE (1999) Chemoprevention of mammary cancer with Se-allylselenocysteine and other selenoamino acids in the rats. Anticancer Res 19: 2875-2880.
29. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens Jr FL, Baker LH, Coltman CA Jr (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers. The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301: 39-51.
30. Miki K, Xu M, Gupta A, Ba Y, Tan Y, Al-Refaie W, Bouvet M, Makuuchi M, Moossa AR, Hoffman RM (2001) Methioninase cancer gene therapy with selenomethionine as suicide prodrug substrate. Cancer Res 61: 6805-6810.
31. Miller LJ, Chandler SW, Ippoliti CM (1994) Treatment of cyclophosphamideinduced hemorrhagic cystitis with prostaglandins. Ann Pharmacother 28: 590-594.
32. Rooseboom M, Schaaf G, Commandeur JN, Vermeulen NP, Fink-Gremmels J (2002) Beta-lyase-dependent attenuation of cisplatin-mediated toxicity by selenocysteine Se-conjugates in renal tubular cell lines. J Pharmacol Exp Ther 301: 884-892.
33. Satoh M, Naganuma A, Imura N (1989) Optimum schedule of selenium administration to reduce lethal and renal toxicities of cisdiamminedichloroplatinum in mice. J Pharmacobiodyn 12: 246-253.
34. Shepherd JD, Pringle LE, Barnett MJ, Klingemann HG, Reece DE, Phillips GL (1991) Mesna versus hyper hydration for the prevention of cyclophosphamide- induced hemorrhagic cystitis in bone marrow transplantation. J Clin Oncol 9: 2016-2020.
35. Spayd RW, Bruschi B, Burdcik BA, Burdick BA, Dappen GM, Eikenberry JN, Esders TW, Figueras J, Goodhue CT, LaRossa DD, Nelson RW, Rand RN, Wu TW (1978) Multilayer film elements for clinical analysis: applications to representative chemical determinations. Clin Chem 24: 1343-1350.
36. Wasserman E, Sutherland W, Cvitkovic E (2001) Irinotecan plus oxaliplatin: a promising combination for advanced colorectal cancer. Clin Colorectal Cancer 1: 149-153.
37. Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL (2002) Acute oxaliplatin induced peripheral nerve hyperexcitability. J Clin Oncol 20: 1767-1774.
38. Zhou H, Smith AH, Steinmaus C (2004) Selenium and lung cancer: a quantitative analysis of heterogeneity in the current epidemiological literature. Cancer Epidemiol Biomarkers Prev 13: 771-778.